13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001388551
Total reported value
$1.9M
$1.9M
11 檔
204.8%
During the Q4 2025 filing period, Caxton CORP (CIK: 0001388551) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $1.9M across 11 reported positions.
In Q4 2025, Caxton CORP adopted a defensive or profit-taking posture, trimming 6 positions and completely liquidating 3 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | GLD | Spdr Gold Shares | ETF-Commodities | 64.50% | -81.50% | EXIT | |
| 2 | BRK-B | Berkshire Hathaway Inc-cl B | Stock-Other | 8.34% | +11.69% | +9.06% | |
| 3 | SYRE | Spyre Therapeutics Inc | Stock-Other | 6.83% | — | — | |
| 4 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 4.91% | — | -41.92% | |
| 5 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 4.12% | +1.91% | -18.31% | |
| 6 | CMPX | Compass Therapeutics Inc | Stock-Other | 3.70% | — | -44.87% | |
| 7 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 3.24% | +2.27% | -19.55% | |
| 8 | XFOR | X4 Pharmaceuticals Inc | Stock-Other | 1.45% | +2.32% | — | |
| 9 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 1.36% | +1.93% | +73.57% | |
| 10 | SABS | Sab Biotherapeutics Inc | Stock-Other | 0.92% | — | -3.73% | |
| 11 | CNTX | Context Therapeutics Inc | Stock-Other | 0.63% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | GLD | Spdr Gold Shares | +53.2% | -4.42% | Trim |
| 2 | BRK-B | Berkshire Hathaway Inc-cl B | +6.9% | +9.06% | Add |
| 3 | BRD1EUR | Mind Medicine Mindmed Inc | +3.5% | -41.92% | Trim |
| 4 | KYTX | Kyverna Therapeutics Inc | +3.5% | -18.31% | Trim |
| 5 | CMPX | Compass Therapeutics Inc | +2.9% | -44.87% | Trim |
| 6 | LXEO | Lexeo Therapeutics Inc | +2.7% | -19.55% | Trim |
| 7 | IKT | Inhibikase Therapeutics Inc | +1.2% | +73.57% | Add |
| 8 | SABS | Sab Biotherapeutics Inc | +0.8% | -3.73% | Trim |
| 9 | CNTX | Context Therapeutics Inc | +0.6% | — | Unchanged |
| 10 | RZLT | Rezolute Inc | — | EXIT | Sold out |
| 11 | SYRE | Spyre Therapeutics Inc | — | NEW | New buy |
| 12 | ELVN | Enliven Therapeutics Inc | — | EXIT | Sold out |
| 13 | BCAX | Bicara Therapeutics Inc | — | EXIT | Sold out |
| 14 | XFOR | X4 Pharmaceuticals Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Caxton CORP reported a total U.S. public equity portfolio value of $1.9M across 11 disclosed positions in Q4 2025.
During Q4 2025, Caxton CORP's top holdings by market value included GLD (64.5%)、BRK-B (8.3%)、SYRE (6.8%). The largest single position, GLD, represented 64.5% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including GLD, BRK-B, SYRE) accounted for 204.8% of total reported equity market value during Q4 2025.
Top New Position Initiated
SYRE
市值: $292.2K
Top Position Liquidated / Trimmed
RZLT
前期市值: $18.7M
In Q4 2025, Caxton CORP made 13 total portfolio adjustments, initiating 2 new buys, adding to 2 positions, trimming 6 holdings, and fully liquidating 3 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.